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Receptors of the EGF receptor or ErbB family of growth factor receptor tyrosine kinases are frequently overexpressed in a variety of
solid tumours, and the aberrant activation of their tyrosine kinase activities is thought to contribute to tumour growth and
progression. Much effort has been put into developing inhibitors of ErbB receptors, and both antibody and small-molecule
approaches have exhibited clinical success. Recently, a number of endogenous negative regulatory proteins have been identified that
suppress the signalling activity of ErbB receptors in cells. These include intracellular RING finger E3 ubiquitin ligases such as cbl and
Nrdp1 that mediate ErbB receptor degradation, and may include a wide variety of secreted and transmembrane proteins that
suppress receptor activation by growth factor ligands. It will be of interest to determine the extent to which tumour cells suppress
these pathways to promote their progression, and whether restoration of endogenous receptor-negative regulatory pathways may
be exploited for therapeutic benefit.
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The ErbB family of receptor tyrosine kinases, consisting of the EGF
receptor, ErbB2, ErbB3 and ErbB4, directs a broad range of
developmental events and contributes to the malignancy of a
number of tumour types. Numerous in vivo and in vitro studies
have shown that ErbB signalling plays essential roles in the
development and maintenance of mammary, cardiac and neural
tissues, and contributes to the development of a variety of other
tissues through epithelial remodelling and differentiation. The
aberrant activation of ErbB receptors in tumours can occur via
mutational activation, receptor overexpression, or through tumour
production of autocrine growth factor ligands.
Owing to the widespread role of ErbB receptor activation in
tumour growth and progression, the development of ErbB
inhibitors has been a subject of intense interest. Indeed,
neutralising antibodies directed towards the EGF receptor or
ErbB2 are either in clinical trials or have received FDA approval
for the treatment of some tumours (Arteaga, 2003). Moreover, a
variety of small-molecule inhibitors are being developed to target
these receptors. In this light, it is of interest to look more closely at
endogenous ErbB receptor-negative regulatory pathways, the
mechanisms by which tumours could overcome these checks on
receptor activity, and whether these mechanisms might be
employed to ultimately benefit patients.
Members of the mammalian ErbB family are acted upon by EGF-
like growth factor ligands, which bind to receptor extracellular
domains to stimulate tyrosine kinase activity. The EGF-like
domain, a 40–60 amino-acid domain characterised by six cysteine
residues forming three disulphide bonds, is a very common
component of the extracellular regions of a variety of proteins
encompassing a wide range of functions. Only a small subset of
EGF-like proteins function as activating ligands for ErbB receptors.
Despite a high degree of sequence similarity, each of the ErbB
receptors appears to possess distinct biochemical and biological
properties. Ligand specificity is determined by the receptor
extracellular domains, and EGF receptor, ErbB3 and ErbB4 each
bind subsets of the known ligands. No diffusible ligand has been
demonstrated to interact with ErbB2. On the other hand, although
all four receptors undergo ligand-stimulated homo- and hetero-
dimerisation events as part of their signalling mechanism, ErbB2
appears to be the preferred heterodimerisation partner for the
other family members. ErbB3 is unique in that it lacks an intrinsic
kinase activity and must necessarily heterodimerise with other
family members to propagate signals. Pertinent to a discussion of
negative regulatory mechanisms, it has been reported that only
EGF receptor undergoes significant ligand-stimulated receptor
internalisation and degradation (Baulida et al, 1996; Baulida and
Carpenter, 1997). The marked differences in the properties of the
ErbB receptors point to the possibility that inhibitory mechanisms
may not adhere to a one-size-fits-all paradigm; cells may employ
different inhibitory mechanisms to negatively regulate the different
ErbB family members. Our purpose here is to discuss the variety of
mechanisms that directly impinge upon ErbB receptors to regulate
their potential to contribute to tumorigenic processes.
RECEPTOR DEGRADATION
One of the primary mechanisms by which cells negatively regulate
growth factor receptor activity is through receptor degradation.
For a quarter century, the EGF receptor has served as a prominent
model for understanding how cell surface receptors undergo
ligand-stimulated downregulation and degradation. In general,
ligand stimulation results in receptor localisation to plasma
membrane clathrin-coated pits, internalisation of coated pits
and delivery to endosomes, and sorting of endosomal receptors
Received 9 July 2003; revised 15 October 2003; accepted 27 October
2003
*Correspondence: Dr C Sweeney; E-mail: casweeney@ucdavis.edu
British Journal of Cancer (2004) 90, 289–293
& 2004 Cancer Research UK All rights reserved 0007– 0920/04 $25.00
www.bjcancer.comfor trafficking back to the cell surface or to lysosomes for
degradation.
Recent years have seen marked advances in our understanding
of the molecular mechanisms underlying these events (Shtiegman
and Yarden, 2003). A key protein that has received a great deal of
attention in this process is cbl, which contains a phosphotyrosine
binding domain and a RING finger E3 ubiquitin ligase domain.
Overexpression of cbl in cells augments EGF-stimulated receptor
ubiquitylation and degradation, and functional RING finger and
phosphotyrosine binding domains are both required for enhanced
degradation (Levkowitz et al, 1998).
Receptor stimulation by EGF results in the phosphorylation of
several tyrosine residues of the receptor intracellular region,
including tyrosine 1045 that acts as a docking site for cbl.
Alternatively, cbl may be recruited in complex with the adaptor
protein Grb2 through a distinct phosphotyrosine residue (Water-
man et al, 2002). Recruited cbl becomes tyrosine phosphorylated
by the receptor, activating its ubiquitin ligase activity (Levkowitz
et al, 1999). cbl is thought to ubiquitylate the receptor on
intracellular lysine residues, perhaps through the attachment of
multiple monoubiquitin moieties (Mosesson et al, 2003), to
mediate receptor trafficking. Interestingly, some EGF receptor
stimulants such as oxidants that promote robust gross receptor
tyrosine phosphorylation do not significantly stimulate the
phosphorylation of tyrosine 1045. This leads to enhanced receptor
stability, and the inability of the EGF receptor to become
downregulated following oxidant exposure could contribute to
the progression of diseases such as lung cancer (Ravid et al, 2002).
The cellular site(s) of cbl action toward the EGF receptor and its
role in internalisation are a point of controversy. While evidence
suggests that cbl is capable of interacting with the receptor prior to
localisation in coated pits (de Melker et al, 2001), and that
attachment of a single ubiquitin moiety to the carboxy terminus of
the receptor may be sufficient to induce receptor internalisation
and degradation (Mosesson et al, 2003), studies using cells derived
from mice lacking a functional cbl gene suggest that cbl-mediated
ubiquitylation is not necessary for EGF-stimulated internalisation
(Duan et al, 2003). It is generally agreed, however, that cbl-
mediated receptor ubiquitylation targets endosomal receptors for
degradation in the lysosome, while nonubiquitylated receptors are
routed back to the cell surface (Figure 1).
Interestingly, cbl has been reported to be an inefficient substrate
of the other ErbB receptors under physiological conditions
(Levkowitz et al, 1996). These observations are consistent with
observations that ErbB2, ErbB3 and ErbB4 do not undergo
significant ligand-induced downregulation, and underscore the
importance of other mechanisms in keeping the activities of these
receptors in check. In the absence of ligand-induced receptor
degradation mechanisms, it becomes much more important to
precisely control cell surface receptor levels. This will ensure
sufficient signalling for cellular events directed toward tissue
development or maintenance, yet prevent oversignalling that could
lead to disease. While to a first approximation, cell surface
receptor levels can be controlled at the transcriptional level, recent
studies suggest that receptor ubiquitylation by novel E3 ubiquitin
ligases may also play a role in the maintenance of steady-state
receptor levels.
Even in the absence of ligand binding, growth factor receptors
undergo constant internalisation and trafficking through endo-
somes. While most internalised receptors are returned to the cell
surface, a small fraction of unoccupied receptors is targeted for
degradation. The competing processes of recycling and degrada-
tion establish an equilibrium that defines receptor half-life and
hence the steady-state levels of cell surface receptors (Wiley, 2003).
For example, in a normal epithelial cell, a growth factor receptor
may be recycled a dozen times prior to its degradation, resulting in
a half-life of 12h. However, in a transformed cell, a smaller fraction
of the trafficked receptors may be targeted for degradation,
resulting in a markedly prolonged receptor half-life and elevated
cell surface receptor levels. Hence, protein(s) involved in targeting
receptors for ligand-independent degradation could play a
significant role in suppressing the tumour growth properties by
suppressing endogenous receptor levels.
Two recent studies have characterised the role of a novel E3
ubiquitin ligase in controlling the cellular levels of ErbB3 and
ErbB4 (Diamonti et al, 2002; Qiu and Goldberg, 2002). Nrdp1 was
originally identified as a RING finger domain-containing protein
that interacts with ErbB3 in a ligand- and phosphotyrosine-
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Figure 1 ErbB receptor-negative regulatory mechanisms. Activation of ErbB receptors (blue) by growth factor binding leads to receptor dimerisation and
phosphorylation on several tyrosine residues (asterisks), while activation by oxidants leads to a subset of receptor phosphorylation events. Active and
inactive receptors are internalised, where they may be acted upon by E3 ubiquitin ligases. Ubiquitylation of unoccupied ErbB3 and ErbB4 after Nrdp1 binding
marks these receptors for degradation. Cbl binds to tyrosine 1045 of ligand-activated EGF receptor to facilitate receptor ubiquitylation and trafficking to
lysosomes. Tyrosine 1045 of oxidant-activated EGF receptor is not phosphorylated, and these receptors are resistant to downregulation. Kek1, argos and
herstatin (HS) are all examples of transmembrane or secreted proteins that interfere with ErbB receptor activation, either by disrupting ligand binding or by
interfering with the dimerisation or activation mechanism.
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Nrdp1 is capable of specifically interacting with ErbB3 and ErbB4,
binding receptors for the neuregulin-1 and neuregulin-2 EGF-like
growth factors, but not with EGF receptor or ErbB2. Like cbl,
Nrdp1 overexpression is capable of specifically suppressing the
cellular levels of its target receptors, and both the receptor-binding
region and the RING finger domain are necessary for this process.
Unlike cbl, Nrdp1 acts similarly on ligand-stimulated and
unstimulated receptors, dramatically lowering the half-life of
ErbB3. Nrdp1-mediated ubiquitylation of ErbB3 in vitro and
relocalisation of ErbB3 from the cell surface into intracellular
compartments suggest that this protein could act to target the
ErbB3 and ErbB4 receptors to degradative compartments, in a
manner analogous to cbl-mediated EGF receptor trafficking and
degradation.
Physiologically, variations in activities of E3 ligases that mark
receptors for degradation could play a role in ensuring that
signalling is temporally confined. For example, following a
particular growth factor-dependent developmental event, upregu-
lation of an E3 ligase activity that targets the corresponding
receptor tyrosine kinase could clear the unoccupied or ligand-
bound receptors to prevent further signalling. In tumour cells, the
suppression of such E3 ligase activity could permit receptor
overexpression and facilitate events associated with tumour
growth and progression. Receptor-specific sorting E3 ligase
activity may be regulated at the transcriptional level, where the
negative regulator could be a transcriptional target of receptor
activation. Alternatively, it has been observed that Nrdp1 is
extremely labile in many cell types and mediates its own
ubiquitylation and degradation through a proteasome-dependent
pathway (Diamonti et al, 2002; Qiu and Goldberg, 2002), raising
the possibility that pathways that specifically stabilise E3 ligase
proteins could augment receptor degradation.
NEGATIVE MODULATOR PROTEINS
A second mechanism by which cells negatively regulate ErbB
receptors is through the use of extrinsic modulator proteins that
physically interact with receptors to determine their response to
ligand binding (Carraway and Sweeney, 2001). Modulators can
either potentiate receptor response to ligand, illustrated by the
augmented signalling observed in the ErbB2–ErbB3 heterodimer
in the presence of ASGP2 or CD44 (Carraway et al, 1999; Sherman
et al, 2000), or they can negatively regulate receptor activity.
One class of naturally occurring negative modulators consists of
splice variants encoding some or most of the extracellular portions
of ErbB receptors. Herstatin is the product of an alternatively
spliced human ErbB2 that leaves intron 8 in the message. The
resulting expressed product encompasses half of the ErbB2
extracellular region along with 79 amino acids encoded by the
retained intron (Doherty et al, 1999). Herstatin binds with high
affinity to EGF receptor and ErbB2, and inhibits ErbB receptor
homo- and heterodimer formation and tyrosine phosphorylation
(Azios et al, 2001). Interestingly, rather than completely inhibiting
ErbB receptor signalling, Herstatin appears to modulate signalling
pathway usage by receptors to elicit cellular growth arrest
(Justman and Clinton, 2002). A similar splice variant of ErbB3
encoding most of the extracellular region followed by intron-
encoded sequence may act as an inhibitor of cell growth by
binding ligand to form nonproductive ligand–receptor complexes
(Lee et al, 2001).
On a more speculative note, studies with the Drosophila
melanogaster EGF receptor point to the possibility that other
negative modulators may exist in humans. Flies have a single EGF
receptor family member that can be stimulated by four EGF-like
growth factors. In addition, two feedback negative regulators that
act directly and specifically on the fly receptor have been
identified. The first, called Argos, contains an unconventional
EGF-like domain that disrupts the spacing between cysteine
residues found in the activating EGF-like ligands. Argos acts as
an antagonist of fly EGF receptor activity (Jin et al, 2000; Vinos
and Freeman, 2000), binding to the receptor with modest affinity
and inhibiting activation by other ligands. Argos is expressed in
response to EGF receptor activation, and is thought to contribute
to receptor inhibition events critical for proper development
(Stevens, 1998). Interestingly, it has been reported that potato
carboxypeptidase inhibitor (CPI), a 39 amino-acid-secreted
protein containing a disulphide-bonded T-knot structure moder-
ately reminiscent of EGF-like domains, acts as an antagonist of the
EGF receptor in human tumour cells (Blanco-Aparicio et al, 1998).
Taken together, these observations point to the possibility that
human proteins containing EGF-like domains with unusually
spaced cysteine residues, or containing other disulphide-bonded
structures, could act as endogenous inhibitory factors for
mammalian ErbB receptor family members. Since dozens of
proteins encompassing hundreds of EGF-like or cysteine knot
domains are encoded by human genes, the list of candidates is
quite extensive. Given that some of the activating ligands contain
other domains as well, it is possible that ErbB antagonistic
domains could be components of proteins typically associated with
unrelated functions.
CPI was shown to inhibit EGF binding to the EGF receptor, EGF-
stimulated receptor tyrosine phosphorylation and cellular prolif-
eration, and was also demonstrated to inhibit the growth of
pancreatic tumour cells in culture and in nude mice. These
observations underscore the possibility that, once identified,
endogenous ErbB antagonists might ultimately be exploited to
inhibit tumour progression in patients.
A second EGF receptor feedback negative regulator identified in
Drosophila is the leucine-rich repeat (LRR) protein kekkon-1
(Kek1). Kek1 was identified in a screen for downstream targets of
fly EGF receptor activation (Musacchio and Perrimon, 1996), and
was later found to inhibit EGF receptor signalling in vivo and in
vitro (Ghiglione et al, 1999). It is a single-pass transmembrane
protein, with a large extracellular region containing an immuno-
globulin-like (Ig) domain and a series of six contiguous leucine-
rich repeats. Although Kek1 has no EGF-like domain, it physically
associates with the fly EGF receptor in vivo to suppress receptor
signalling (Ghiglione et al, 2003). The leucine-rich repeat region of
Kek1 is necessary for EGF receptor binding and inhibition.
Interestingly, the fly Kek1 protein is capable of interacting with
all four members of the mammalian ErbB receptor family, and
inhibits signalling through the human EGF receptor (Ghiglione
et al, 2003). Moreover, it potently inhibits the growth of human
breast tumour cell lines and some mouse mammary tumour cell
lines in soft agar assays and in xenografts. Specifically, the growth
of cell lines derived from mouse tumours arising from activated
ErbB2 or from ErbB3 ligand overexpression was inhibited by Kek1
expression, while the growth of a cell line derived from a tumour
arising from activated ras was not inhibited.
These results also beg the question of whether or not a human
Kek1 homologue exists. Owing to its ability to inhibit ErbB
activity, such a protein could be the product of a tumour-
suppressor gene whose function is lost in some tumours. The
search for a mammalian Kek1 homologue focuses on proteins
containing leucine-rich repeats in their extracellular regions. This
encompasses a wide variety of proteins such as growth factor
receptors, growth factor-binding proteins and proteoglycans,
among others. A subset of roughly a dozen of these contains both
an LRR region and one or more Ig domains. Given that the Ig
domain of Kek1 is dispensable for both EGF receptor binding and
suppression of signalling in flies (Ghiglione et al, 2003), it is
unclear whether the human form would possess this domain.
Nonetheless, an attractive candidate called Lig-1 emerges from
this list.
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expression is induced upon retinoic acid-induced differentiation of
P19 neuronal embryonic carcinoma cells (Suzuki et al, 1996). Its
extracellular region contains 15 leucine-rich repeats and three Ig
domains. Targeted disruption of the Lig-1 gene in mice yields
hyperplastic epidermal lesions reminiscent of psoriasis as a result
of keratinocyte hyperproliferation (Suzuki et al, 2002), and a
comparison of human tissue samples showed a loss of Lig-1
expression in psoriatic skin. Since autocrine activation of the EGF
receptor is a major contributor to keratinocyte proliferation in
psoriasis, these observations point to the possibility that Lig-1
negatively regulates EGF receptor. Moreover, real-time RT–PCR
analysis showed a loss of Lig-1 expression in tumour cell lines
relative to normal tissues, raising the possibility that Lig-1 is the
product of a tumour-suppressor gene (Hedman et al, 2002).
However, the impact of Lig-1 on ErbB receptor signalling and on
the regulation of tumour cell growth remains to be determined.
Finally, recent evidence suggests that a putative L1-type cell
adhesion molecule may interact directly with the Drosophila EGF
receptor to inhibit its activity. Echinoid, a Drosophila transmem-
brane protein that contains seven Ig domains and two fibronectin
type III domains in its extracellular region, was originally identified
as a negative regulator of EGF receptor-mediated eye development
in flies (Bai et al, 2001). This study suggested that Echinoid acts in a
separate parallel pathway to negatively regulate signalling down-
stream of the EGF receptor. However, more recent studies suggest
that Echinoid acts at the receptor in flies (Rawlins et al, 2003), and
that EGF receptor physically associates with Echinoid and mediates
its tyrosine phosphorylation when the two proteins are coexpressed
in cultured cells (Spencer and Cagan, 2003). In contrast with Kek1
and Argos, Echinoid does not appear to be a transcriptional target
of EGF receptor, and it may act through a mechanism that involves
inhibition of receptor signalling rather than receptor activation.
Despite the actual mechanism, these observations again raise the
possibility that a human homologue of Echinoid may be involved in
the negative regulation of human ErbB family receptors.
CONCLUSIONS
It is becoming increasingly clear that cells employ a variety of
mechanisms to prevent oversignalling by the ErbB growth
factor receptors. Degradation of receptors, mediated by E3
ubiquitin ligases associated with intracellular sorting compart-
ments, may play a central role in suppressing signalling following
ligand activation or in maintaining a narrow window of receptors
at the cell surface, which are available for ligand activation.
Transmembrane and secreted modulator proteins can physically
interact with receptors to antagonise ligand binding or to
interfere with the receptor activation mechanism. Studies from
Drosophila offer novel candidates for negative regulators, and
newly developed rapid protein–protein interaction screening
techniques (Stagljar and Fields, 2002) could facilitate the
identification of functional mammalian homologues. In addition,
a number of intracellular proteins such as sprouty, Dok, and some
tyrosine phosphatases have been shown to suppress signalling
following receptor activation. However, such proteins may
function more in fine-tuning receptor signalling than in control-
ling the overall receptor output. It is also apparent that the
different ErbB receptor family members are regulated by different
mechanisms. For example, the absence of ligand-stimulated
neuregulin receptor degradation highlights the need for other
negative regulatory mechanisms for these receptors, such as
Herstatin and Nrdp1.
While preliminary work has been carried out on some of
these negative regulators, the extent to which most of these
pathways are suppressed in tumours remains to be explored. It is
likely that the function of pathway components, such as E3 ligases
associated with receptor expression levels, is lost in tumours
associated with ErbB overexpression. The restoration of these
pathways, particularly those involving proteins with extracellular
regions that interact with ErbB receptors, could offer a novel
approach to suppressing the growth properties of ErbB-dependent
tumours.
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